24/7 Market News Snapshot 17 March, 2025 – CervoMed Inc. Common Stock (NASDAQ:CRVO)

March 17, 2025

DENVER, Colo., 17 March, 2025 (247marketnews.com) – (NASDAQ:CRVO) are discussed in this article.
CervoMed Inc. (NASDAQ:CRVO), a clinical-stage biotech firm focused on developing treatments for age-related neurological disorders, is experiencing a substantial market surge, with its stock price rising over 20% from $6.44 to $7.744. This increase reflects heightened investor confidence, as evidenced by a trading volume of 2.03 million shares. The surge comes on the heels of CervoMed’s announcement regarding promising results from its Phase 2b RewinD-LB trial, which studied neflamapimod as a potential treatment for dementia with Lewy bodies (DLB).

The trial’s findings indicate significant improvements in the primary outcome measure, suggesting that neflamapimod could be a transformative therapeutic option for managing DLB. CervoMed is set to advance these developments by initiating a Phase 3 trial in mid-2026, following discussions with regulatory authorities. Dr. John Alam, Chief Executive Officer of CervoMed, expressed optimism about the results, emphasizing their validation of the company’s approach in addressing DLB.

In recognition of its commitment to innovation, CervoMed was awarded the prestigious 2024 Prix Galien USA award for “Best Startup,” underscoring its impact in the life sciences sector. The findings from the trial will be shared at the upcoming 19th International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurologic Disorders (AD/PD™) in April 2025, a platform aimed at disseminating valuable insights to the global scientific community.

Moreover, CervoMed plans to explore additional applications for neflamapimod, including a Phase 2a trial for frontotemporal dementia and a Pediatric Restore Trial for patients recovering from ischemic stroke. With a strong cash position and increased grant revenues expected to bolster its operations, CervoMed is well-positioned for continued growth and innovation in neurodegenerative disease management, with further updates anticipated throughout 2025.

Related news for (CRVO)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.